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Influence of hematocrit on hemostasis in continuous venoven- treatment modality for patients with acute renal failure
ous hemofiltration during acute renal failure. [1]. Since then, various other regimens for continuous
Background. Hematocrit plays a major role in primary he- renal replacement therapy, for example, continuous ve-mostasis by influencing blood viscosity and platelet adhesion.
novenous hemofiltration (CVVH), have been developed.During continuous venovenous hemofiltration (CVVH), it is
CVVH is especially suitable in patients with water andsuspected that an increased hematocrit is accompanied by an
activation of hemostasis and frequently leads to thromboses electrolyte imbalances that are hemodynamically unsta-
in the extracorporeal system. In order to examine this hypothe- ble [2]. The latter advantage and its ability to treat uremia
sis, we studied the influence of hematocrit on hemostasis during effectively, even in cases of hypercatabolism, have ledCVVH.
to the rapid spread of this modality in recent years [3].Methods. Fourteen patients (8 men and 6 women, mean age
Bleeding represents an important morbidity and mor-65 6 10 years) with acute renal failure undergoing CVVH were
prospectively enrolled. Polysulfone hemofilters (AV 600t; Fre- tality factor in acute renal failure (ARF), and therefore,
senius, Oberursel, Germany) were used in all of the patients; changes in hemostasis during CVVH may influence the
blood flow rates were adjusted to 120 ml/min. No blood prod-
prognosis of ARF [4, 5]. The continuous contact betweenucts and coagulation-related medication, except unfractionated
blood and thrombogeneic foreign materials (hemofilter,heparin, were applied. Study exclusion criteria included a his-
tory of thromboembolism and artificial heart valves. Hemosta- extracorporeal circulation system), inherent in CVVH,
sis activation markers (fibrinopeptide A, thrombin-antithrom- activates the coagulation cascade, necessitating intrave-
bin III complex, b-thromboglobulin, platelet retention) and nous anticoagulation treatment. These factors may lead
hematocrit values were determined before and at three-day
to pronounced alterations in hemostasis during CVVH.intervals during the course of CVVH treatment.
Hematocrit plays a major role in primary hemostasisResults. The mean hematocrit value (X 6 sem) was 29 6
1% (range, 22 to 35%). Patients with hematocrit values of less by influencing blood viscosity and platelet adhesion [6].
than 30% (N 5 7) were compared with patients with higher It is therefore suspected that higher hematocrit values
hematocrit values (.30%, N 5 7). The patients with a lower may lead to a more pronounced activation of hemostasishematocrit (,30%) showed a stronger activation of hemostasis
and more frequent thromboses in the extracorporeal sys-during CVVH when compared with those with a higher hema-
tem during CVVH [7]. The objective of this study istocrit (.30%), as indicated by a tendency toward higher values
for fibrinopeptide A (25 6 8 vs. 14 6 5 ng/ml, P 5 0.35), to determine whether changes in hemostasis (plasmatic
thrombin-antithrombin III complex (15 6 4 vs. 10 6 2 ng/ml, coagulation, platelets) that occur during CVVH are in-
P 5 0.66), and a higher b-thromboglobulin/creatinine ratio
fluenced by variations of hematocrit values.(0.62 6 0.17 vs. 0.48 6 0.12, P 5 0.8).
Conclusion. Contrary to our hypothesis, hematocrit values
of more than 30% are not accompanied by an increased hemo-
METHODSstasis activation during CVVH. Concerning hemostasis activa-
tion, hematocrit values between 30 and 35% may be suitable We prospectively examined 14 patients (8 men and 6
for patients on CVVH. women, mean age 65 6 10 years) with acute renal failure
of varying origin (Table 1) who were undergoing CVVH
treatment in an intensive care unit. Patients with pre-
Continuous arteriovenous hemofiltration (CAVH) existing disseminated intravascular coagulation (DIC),
was reported by Kramer et al in 1977 as a continuous venous thrombosis, arterial and pulmonary embolism,
or thrombosis, and patients with artificial heart valves
were excluded from the study. The patients receivedKey words: blood coagulation, CVVH, platelet function, thrombosis,
water and electrolytes, hemodynamics. no coagulation-related medication except heparin during
CVVH. Fibrinopeptide A, thrombin-antithrombin III 1999 by the International Society of Nephrology
S-51
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Table 1. Profiles of patients undergoing continuous venovenous hemofiltration
Case No. Age Sex Diagnosis Days on CVVH DIC Bleeding Outcome
1 79 f Cerebral hemorrhage 7 2 2 Died
2 71 m Pneumonia 19 2 1 Died
3 71 f Cholangitis 16 2 2 Died
4 65 f Cerebral hemorrhage 4 2 2 Died
5 69 m ACVB operationa 29 2 2 Died
6 50 m Heart failure 7 2 2 Survived
7 61 f Septic shock 11 2 2 Died
8 66 m Pneumonia, ARDSb 3 2 2 Died
9 74 m ACVBa operation 9 2 2 Survived
10 45 m Pneumonia 12 2 1 Survived
11 60 m Septic shock 6 2 2 Survived
12 81 m Cardiogenic shock 5 2 1 Died
13 51 f Pneumonia 3 2 2 Died
14 61 f Cardiogenic shock 9 2 2 Died
Mean 65 10.0
sd 10 7.2
a Aortocoronary venous bypass
b Adult respiratory distress syndrome
complex, b-thromboglobulin, and platelet retention were concentrations [8, 9]. Whole blood was taken and pro-
determined before and at three-day intervals during cessed immediately with Adeplat S glass bead filters
treatment. Patients with hematocrit values of less than (Semmelweis, Milan, Italy) to determine Hellem II plate-
30% (N 5 7) were compared with patients with higher let retention [10]. Platelet counts were performed before
hematocrit values (.30%, N 5 7). and after being filtered with the differences (retention)
A standardized CVVH technique was employed in all expressed as a percentage of the total platelet count
patients. Percutaneously introduced double-lumen ve- before filtering (reference 60% to 99%). The reduction
nous catheters (Shaldon catheters, 1.8 mm diameter) of platelet retention indicates an impaired platelet adhe-
were used for vascular access (internal jugular, subcla- siveness [11]. The remaining plasmatic coagulation tests
vian as femoral vein). The filters used were polysulfone were performed with a ball coagulometer (KC 10; Amel-
hemofilters with a filtration surface of 1.35 m2 (AV 600t; ung, Lemgo, Germany) or a digital photometer (6114 S;
Fresenius, Oberursel, Germany). Blood flow rates were Eppendorf, Hamburg, Germany). ACT was measured
adjusted to approximately 120 ml/min with substitution immediately after blood sampling with an ACTestert
fluid administration in a postdilution mode. Filtration (Trimed, Huntington, CA, USA). The whole blood
rates were approximately 20 ml/min in order to maintain count and the hematocrit from ethylenediaminetetraace-
urea concentrations at approximately 20 mmol/liter. An tic acid (EDTA)-anticoagulated blood (1 mg EDTA/ml
unfractionated heparin (Liquemint; Roche, Basel, Swit- blood) was determined with an electronic cell counter
zerland) was used as anticoagulant. Low-dose heparin (System 900; Serono Diagnostics, Freiburg, Germany).
was administered intravenously in all patients (500 If not otherwise indicated, data are expressed as mean
IU/hr) before the initiation of CVVH treatment. During values 6 sem (X 6 sem). The probability of error for
CVVH, the heparin dosage was adjusted via the acti- comparison of the measured values was calculated using
vated clotting time (ACT) with a target ACTs of more the Wilcoxon signed rank test for paired data and the
than 110 seconds. Mann–Whitney U-test for unpaired data. The interde-
Blood samples for coagulation tests were collected in pendence of the different variables was checked by
polypropylene tubes (Sarstedt, Nu¨mbrecht, Germany) means of a Pearson correlation analysis.
containing citrate (one part sodium citrate 3.8% and 9
parts blood) and centrifuged at 3000 g for 15 minutes at
RESULTS48C to obtain platelet-poor plasma (cPPP). Blood sam-
Fibrinopeptide A (33 6 6 ng/ml, reference ,3.0) andples for b-thromboglobulin determinations were col-
thrombin-antithrombin III complex (11 6 1.5 ng/ml, ref-lected in glass tubes with CTAD (citrate, theophylline,
erence 1.0 to 4.0) concentrations were elevated beforeadenosine, dipyridamole) as the anticoagulant. Enzyme-
initiation of CVVH, and no further rise of these parame-linked immunosorbent assay (ELISA) was used to deter-
ters could be observed during CVVH treatment. Plateletmine fibrinopeptide A, b-thromboglobulin (Boehringer,
retention, which was reduced prior to CVVH (39 6 10%,Mannheim, Germany), and thrombin-antithrombin III
complex (Behringwerke, Marburg, Germany) plasma reference 60 to 99), fell to 16 6 6% after CVVH, whereas
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Fig. 2. Platelet retention before (j) and during (h) treatment by con-
tinuous venovenous hemofiltration (CVVH) in patients (N 5 7) withFig. 1. Plasmatic coagulation parameters [(j) fibrinopeptide A, (h)
low hematocrit values (,30%) compared with patients (N 5 7) withthrombin-antithrombin III complex] during treatment by continuous
high hematocrit values (.30%). The values are plotted as mean andvenovenous hemofiltration (CVVH) in patients (N 5 7) with low hema-
sem (X 6 sem).tocrit values (,30%) compared with patients (N 5 7) with high hemato-
crit values (.30%). The values are plotted as mean and sem (X 6 sem).
b-thromboglobulin/creatinine ratios (reference 0.23 to
0.41) increased from 0.39 6 0.06 before to 0.64 6 0.18
after CVVH.
Antithrombin III concentrations were slightly lower
than normal (17.4 6 3.5 U/ml, reference 18 to 23), and
the fibrinogen concentrations were higher than normal
(565 6 138 mg/dl, reference 200 to 450) before com-
mencement of CVVH.
Hemoglobin values (range, 76 to 125 g/liter) and hema-
tocrit (range, 22 to 35%) were decreased in all patients.
Patients with a lower hematocrit (,30%, N 5 7) showed
increased fibrinopeptide A (25 6 8 vs. 14 6 5 ng/ml,
P 5 0.35) and thrombin-antithrombin III complex (15 6 4
vs. 10 6 2 ng/ml, P 5 0.66) concentration during CVVH
treatment when compared with patients with a higher
hematocrit (.30%, N 5 7), without reaching statistical
significance (Fig. 1).
Intercomparison of patients with hematocrit values Fig. 3. Ratio of b-thromboglobulin/creatinine before (j) and during
(h) treatment by continuous venovenous hemofiltration (CVVH) inless than 30% and patients with higher hematocrit values
patients (N 5 7) with low hematocrit values (,30%) compared with(.30%) also showed no significant difference in platelet
patients (N 5 7) with high hematocrit values (.30%). The values are
retention (26 6 6 vs. 34 6 14%, P 5 0.7). b-Throm- plotted as mean and sem (X 6 sem).
boglobulin/creatinine ratios (0.62 6 0.17 vs. 0.48 6 0.12;
P 5 0.8) were not significantly different during CVVH
treatment in both groups (Figs. 2 and 3).
quent complication of multiorgan failure [12–14]. Fur-
thermore, renal replacement therapy by CVVH may in-
DISCUSSION fluence hemostasis in different ways. Blood contact with
Uremia influences hemostasis in acute renal failure, foreign materials (for example, hemofilters, blood tubes)
and with air (for example, in the venous bubble trap)inducing uremic thrombocytopathy, and DIC is a fre-
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may activate coagulation. In addition, there are major In conclusion, hematocrit values of greater than 30%
up to 35% were not accompanied by an increased hemo-perturbations and mechanical damage of blood cells by
the pump (shear stress). A study of the resultant hemo- stasis activation either before or during the CVVH treat-
ment. These results suggest that, concerning hemostasisstatic alterations in patients with acute renal failure poses
a difficult problem. activation, hematocrit values can be safely maintained
between 30 and 35% in patients with acute renal failureThe contact between blood and thrombogeneic for-
eign materials during CVVH has already been shown to on CVVH.
induce a pronounced platelet activation [15]. An increase
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shear stress, and thereby may strongly contribute to the
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